7Baggers

CymaBay Therapeutics, Inc
(NASDAQ:CBAY) 

CBAY stock logo

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has com...

Founded: 1988
Full Time Employees: 36
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 
                                              
      collaboration revenue
    		57,000  31,016,000                      5,207,000   4,793,000               
      operating expenses:
    		                                          
      research and development
    		22,749,000 19,962,000 19,537,000 18,551,000 16,230,000 15,459,000 17,891,000 18,415,000 18,405,000 17,010,000 16,745,000 12,382,000 -25,158,118 7,743,000 7,942,000 9,509,000 -62,816,163 23,193,000 21,119,000 18,588,000 16,397,000 17,853,000 14,397,000 9,477,000 6,669,000 4,184,000 4,044,000 4,041,000 3,848,000 3,534,000 4,131,000 4,428,000 4,051,000 4,528,000 4,260,000 4,187,000 5,277,000 3,848,000 4,083,000 2,615,000 1,363,000 703,000 
      general and administrative
    		19,806,000 12,245,000 11,578,000 8,324,000 7,247,000 5,904,000 5,878,000 6,087,000 6,104,000 5,179,000 6,521,000 5,236,000 -12,221,575 4,494,000 3,398,000 4,347,000 -14,686,762 4,514,000 4,529,000 5,663,000 4,158,000 3,276,000 3,574,000 3,373,000 2,894,000 2,210,000 3,582,000 3,701,000 2,839,000 2,130,000 2,215,000 2,461,000 1,796,000 2,201,000 2,285,000 2,589,000 2,332,000 1,687,000 1,666,000 2,500,000 2,091,000 683,000 
      total operating expenses
    		42,555,000 32,207,000 31,115,000 26,875,000 23,477,000 21,363,000 23,769,000 24,502,000 24,509,000 22,189,000 23,266,000 17,618,000 -36,676,398 11,650,000 11,152,000 13,927,000 -77,497,850 27,707,000 25,648,000 24,251,000 20,555,000 21,129,000 17,971,000 12,850,000 9,563,000 6,394,000 7,626,000 7,742,000 6,687,000 5,664,000 6,346,000 6,889,000 5,847,000 6,729,000 6,545,000 6,776,000 7,609,000 5,535,000 5,749,000 5,115,000 3,454,000 1,386,000 
      income from operations
    		-42,498,000 -32,207,000 -99,000 -26,875,000 -23,477,000 -21,363,000 -23,769,000 -24,502,000 -24,509,000 -22,189,000 -23,266,000 -17,618,000 36,676,398 -11,650,000 -11,152,000 -13,927,000 77,497,850 -27,707,000 -25,648,000 -24,251,000 -20,555,000 -21,129,000 -17,971,000 -12,850,000 -4,356,000 -6,394,000 -7,626,000 -2,949,000 -6,687,000 -5,664,000 -6,346,000 -6,889,000 -5,847,000 -6,729,000 -6,545,000 -6,776,000 -7,609,000 -5,535,000 -5,749,000 -5,115,000 -3,454,000 -1,386,000 
      yoy
    		81.02% 50.76% -99.58% 9.68% -4.21% -3.72% 2.16% 39.07% -166.82% 90.46% 108.63% 26.50% -52.67% -57.95% -56.52% -42.57% -477.03% 31.13% 42.72% 88.72% 371.88% 230.45% 135.65% 335.74% -34.86% 12.89% 20.17% -57.19% 14.37% -15.83% -3.04% 1.67% -23.16% 21.57% 13.85% 32.47% 120.30% 299.35%     
      qoq
    		31.95% 32432.32% -99.63% 14.47% 9.90% -10.12% -2.99% -0.03% 10.46% -4.63% 32.06% -148.04% -414.82% 4.47% -19.93% -117.97% -379.70% 8.03% 5.76% 17.98% -2.72% 17.57% 39.85% 195.00% -31.87% -16.16% 158.60% -55.90% 18.06% -10.75% -7.88% 17.82% -13.11% 2.81% -3.41% -10.95% 37.47% -3.72% 12.39% 48.09% 149.21%  
      other income, net:
    		                                          
      interest income
    		5,680,000 3,170,000 2,627,000 2,013,000 919,000 677,000 321,000 98,000 27,000 29,000 44,000 67,000 -1,492,384 229,000 426,000 839,000 -4,205,658 1,425,000 1,610,000 1,176,000 1,106,000 1,113,000 1,061,000 708,000 324,000 216,000 44,000 37,000 30,000 45,000 48,000 53,000 61,000 46,000 26,000 27,000 26,000 19,000 17,000 12,000 9,000  
      interest expense
    		-5,081,000 -4,843,000 -4,618,000 -4,403,000 -4,075,000 -3,819,000 -3,648,000 -3,365,000 -2,061,000 -522,000             -128,000 -208,000 -234,000 -258,000 -283,000 -305,000 -328,000 -341,000 -336,000 -332,000 -329,000 -265,000 -165,000 -154,000 -190,000 -191,000 -189,000 -184,000 -182,000 -219,000 
      other income
    		-3,000 -2,000 1,282,000 487,000   2,000               1,453,000 -86,000 -4,655,000 -777,000 -1,798,000 -1,064,000 -2,134,000 33,000 81,000 -358,000 320,000 136,000 1,083,000 5,327,000 4,575,000 -4,949,000 -254,000 2,749,000 -4,775,000 -287,000 298,000 
      total other income
    		596,000 -1,675,000 -709,000 -1,903,000 -2,433,500 -3,142,000 -3,325,000 -3,267,000 -2,034,000 -493,000   -1,492,384 229,000 426,000 839,000 -4,205,658 1,425,000 1,610,000 1,176,000 1,106,000 2,566,000                     
      net income
    		-41,902,000 -33,882,000 -808,000 -28,778,000 -26,633,000 -24,505,000 -27,094,000 -27,769,000 -26,543,000 -22,682,000 -23,222,000 -17,551,000 35,184,014 -11,421,000 -10,726,000 -13,088,000 73,292,192 -26,282,000 -24,038,000 -23,075,000 -19,449,000 -18,563,000 -17,531,000 -17,005,000 -5,043,000 -8,234,000 -8,929,000 -5,351,000 -6,952,000 -5,879,000 -6,992,000 -6,848,000 -5,979,000 -5,865,000 -1,357,000 -2,328,000 -12,722,000 -5,961,000 -3,172,000 -10,062,000 -3,914,000 -1,307,000 
      yoy
    		57.33% 38.27% -97.02% 3.63% 0.34% 8.04% 16.67% 58.22% -175.44% 98.60% 116.50% 34.10% -51.99% -56.54% -55.38% -43.28% -476.84% 41.58% 37.12% 35.70% 285.66% 125.44% 96.34% 217.79% -27.46% 40.06% 27.70% -21.86% 16.27% 0.24% 415.25% 194.16% -53.00% -1.61% -57.22% -76.86% 225.04% 356.08%     
      qoq
    		23.67% 4093.32% -97.19% 8.05% 8.68% -9.56% -2.43% 4.62% 17.02% -2.33% 32.31% -149.88% -408.06% 6.48% -18.05% -117.86% -378.87% 9.34% 4.17% 18.64% 4.77% 5.89% 3.09% 237.20% -38.75% -7.78% 66.87% -23.03% 18.25% -15.92% 2.10% 14.53% 1.94% 332.20% -41.71% -81.70% 113.42% 87.93% -68.48% 157.08% 199.46%  
      other comprehensive income:
    		                        -3,000 -12,000 1,000 -1,000               
      unrealized gain on marketable securities, net of tax
    		206,000 62,000 -54,000 256,000                     -3,000 -12,000 1,000 -1,000 4,750 3,000 -4,000            
      total other comprehensive income
    		206,000 62,000 -54,000      -2,250 -2,000 7,000  -2,072 -104,000 316,000 -210,000 58,750 -51,000 183,000 103,000 3,250 36,000                     
      comprehensive loss
    		-41,696,000 -33,820,000 -862,000 -28,522,000 -26,385,000 -24,638,000 -27,316,000 -27,975,000 -26,555,000 -22,684,000 -23,215,000 -17,565,000 35,181,942 -11,525,000 -10,410,000 -13,298,000 73,057,330 -26,333,000 -23,855,000 -22,972,000 -19,476,000 -18,527,000 -17,466,000 -17,093,000 -5,074,000 -8,246,000 -8,928,000 -5,352,000 -6,951,000 -5,876,000 -6,996,000 -6,828,000 -5,992,000 -5,860,000 -1,363,000 -2,321,000 -12,721,000 -5,976,000 -3,174,000 -10,061,000 5,377,000 -4,343,000 
      basic and diluted net income per common share
    		-370 -320 -10 -290 -310 -280 -310 -320 -350 -330 -340 -250 509.26 -170                          -1,020   
      weighted-average common shares outstanding used to calculate basic and diluted net income per common share
    		106,204,273,000 105,717,996,000 102,150,390,000 97,971,081,000 87,804,063,000 87,804,272,000 87,802,939,000 87,802,939,000 71,055,331,000 69,022,937,000 68,985,461,000 68,946,092,000 68,893,127 68,887,092,000                          9,873,687,000   
      other comprehensive loss:
    		                       -88,000                   
      total other comprehensive loss
    		   256,000 248,000 -133,000  -206,000    -14,000                               
      unrealized loss on marketable securities
    		    -140,250 -133,000  -206,000    -14,000            -88,000             -4,250 -15,000     
      unrealized gain on marketable securities
    		      -222,000  -2,250 -2,000 7,000  -2,072 -104,000 316,000 -210,000 -234,862 -51,000 183,000 103,000 -27,000 36,000 65,000         20,000 1,500 5,000 -6,000 7,000   -2,000 1,000   
      total other comprehensive gain
    		      -222,000                                    
      restructuring charges
    		            -176,000 -587,000 -188,000 71,000                           
      other income:
    		                                          
      basic net income per common share
    		              -160 -190 1,098.47 -380 -350 -370 -320 -310 -300 -320 -80 -210 -310 -200 -300 -250 -300 -290 -270 -270 -90 -150 -930 -440 -320  536,850 422,950 
      diluted net income per common share
    		              -160 -190 1,098.47 -380 -350 -370 -330 -340 -300 -320 -80 -210 -310 -200 -300 -250 -300 -290 -250 -270 -90 -440 -930 -440 -560  5,400 -1,790 
      weighted-average common shares outstanding used to calculate basic net income per common share
    		              68,885,108,000 68,882,459,000 67,033,046 68,701,043,000 68,697,735,000 61,890,632,000 57,808,254,000 59,121,600,000 58,833,647,000 53,752,753,000 34,903,960,000 40,035,690,000 28,752,451,000 26,609,931,000 23,447,003,000 23,447,003,000 23,447,003,000 23,447,003,000 18,900,473,000 21,674,742,000 15,258,363,000 15,099,567,000 12,048,985,000 13,468,081,000 10,064,819,000   101,358,000 
      weighted-average common shares outstanding used to calculate diluted net income per common share
    		              68,885,108,000 68,882,459,000 67,033,046 68,701,043,000 68,697,735,000 61,890,632,000 57,838,299,000 59,387,780,000 58,905,898,000 53,752,753,000 34,903,960,000 40,035,690,000 28,752,451,000 26,609,931,000 23,447,003,000 23,447,003,000 23,447,003,000 23,447,003,000 18,917,213,000 21,674,742,000 15,258,363,000 15,743,167,000 12,048,985,000 13,468,081,000 10,487,393,000  2,845,609,000 731,970,000 
      loss on extinguishment of debt
    		                      -407,000                    
      other comprehensive income
    		                      65,000      1,000 3,000 -4,000 20,000 1,500 5,000 -6,000 7,000   -2,000 1,000   
      net income attributable to common stockholders
    		                                    -12,722,000 -5,961,000 -3,172,000 -10,062,000   
      other comprehensive loss
    		                                    1,000 -15,000     
      accretion to redemption value of redeemable convertible preferred stock
    		                                        -2,322,250 -3,036,000 
      other comprehensive loss/income:
    		                                          
      contract revenue
    		                                          
      net income attributable to stockholders
    		                                        -3,862,000 -4,343,000 
      unrealized losses on marketable securities
    		                                          
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 
                                                
        assets
      		                                          
        current assets:
      		                                          
        cash and cash equivalents
      		206,535,000 273,721,000 35,482,000 59,150,000 20,291,000 30,691,000 52,753,000 73,995,000 125,806,000 68,963 32,897,000 43,326,000 28,193 47,273,000 96,051,000 56,794,000 24,869 43,462,000 28,081,000 125,574,000 48,995,000 41,795,000 44,726,000 65,581,000 23,054,000 23,009,000 9,509,000 13,673,000 10,495,000 6,821,000 12,411,000 21,197,000 7,706,000 6,691,000 11,702,000 10,841,000 11,586,000 16,356,000 8,002,000 22,342,000 24,401,000 32,080,000 
        marketable securities
      		187,720,000 165,057,000 178,362,000 177,215,000 115,194,000 122,724,000 111,130,000 114,564,000 60,729,000 44,825 73,237,000 82,132,000 118,130 113,991,000 72,856,000 119,438,000 166,076 175,132,000 213,126,000 139,182,000 129,669,000 156,350,000 167,353,000 163,955,000 74,156,000 79,160,000 7,217,000 9,723,000 6,499,000 16,313,000 16,705,000 14,057,000 33,774,000 40,162,000 15,329,000 21,950,000 23,209,000 26,270,000 15,624,000 6,191,000 6,843,000  
        prepaid expenses and other current assets
      		9,547,000 8,881,000 10,227,000 6,355,000 2,588,000                                      
        total current assets
      		403,802,000 447,659,000 224,071,000 242,720,000 138,073,000 155,124,000 166,611,000 192,046,000 191,099,000 119,576 113,813,000 133,273,000 151,585 166,129,000 174,102,000 185,949,000 202,923 227,771,000 249,813,000 270,064,000 181,562,000 202,255,000 216,715,000 231,176,000 103,544,000 103,659,000 17,869,000 24,557,000 18,528,000 24,480,000 30,164,000 36,490,000 42,794,000 48,573,000 28,303,000 34,492,000 37,229,000 44,399,000 25,432,000 30,933,000 32,239,000 32,113,000 
        non-current marketable securities
      		21,932,000      6,874,000 4,885,000 8,067,000                                  
        property and equipment
      		465,000 453,000 626,000 729,000 701,000 845,000 993,000 1,024,000 1,178,000 1,341 1,511,000 1,690,000 1,761 1,929,000 2,075,000 2,242,000 2,409 2,549,000 2,693,000 2,794,000 2,905,000 90,000 90,000 103,000 69,000 51,000 59,000 68,000 77,000 85,000 90,000 59,000 64,000 69,000 75,000 80,000 86,000 91,000 87,000 60,000 3,000 9,000 
        right-of-use assets
      		5,260,000                                          
        other assets
      		3,227,000 2,879,000 1,854,000 1,733,000 2,909,000 3,081,000 3,026,000 2,448,000 1,720,000 1,721 1,447,000 1,446,000 207 160,000 160,000 160,000 160 1,261,000 730,000 1,122,000 2,280,000 1,363,000 1,363,000 980,000 634,000 634,000 804,000 754,000 754,000 221,000 221,000 221,000 221,000 221,000 292,000 158,000 159,000 159,000 514,000 203,000 258,000 42,000 
        total assets
      		434,686,000 451,048,000 226,650,000 245,319,000 141,852,000 159,247,000 177,724,000 200,642,000 202,318,000 122,902 117,041,000 136,682,000 153,825 168,486,000 176,597,000 188,600,000 205,727 231,800,000 253,435,000 274,157,000 186,747,000 203,708,000 218,168,000 232,259,000 104,247,000 104,344,000 18,732,000 25,379,000 19,359,000 24,786,000 30,475,000 36,770,000 43,079,000 48,863,000 28,670,000 34,730,000 37,474,000 44,649,000 26,033,000 31,196,000 32,500,000 32,164,000 
        liabilities and stockholders’ equity
      		                                          
        current liabilities:
      		                                          
        accounts payable
      		3,828,000 2,731,000 4,589,000 1,633,000 1,096,000 479,000 866,000 199,000 2,728,000 764 1,050,000 1,606,000 231 947,000 476,000 1,213,000 2,503 1,494,000 2,882,000 2,410,000 1,973,000 1,629,000 1,336,000 2,038,000 1,311,000 1,235,000 1,101,000 1,096,000 899,000 935,000 1,272,000 1,777,000 1,008,000 707,000 1,721,000 1,527,000 2,085,000 1,047,000 1,262,000 1,069,000 697,000 1,039,000 
        accrued research and development expenses
      		5,633,000 5,835,000 4,838,000 5,565,000 6,530,000 6,622,000 7,028,000 9,659,000 9,752,000 6,451 4,126,000 3,294,000 4,698 5,729,000 5,437,000 7,351,000 9,218 10,819,000                         
        development financing liability - current portion
      		10,000,000                                          
        deferred collaboration revenue - current portion
      		1,689,000                                          
        other accrued liabilities
      		15,693,000 9,468,000 6,835,000 5,569,000 7,815,000 5,610,000 4,666,000 4,181,000 5,886,000 4,526 3,783,000 3,009,000 4,910 3,693,000 2,686,000 1,641,000 2,722 5,045,000 3,266,000 2,782,000 3,854,000 2,437,000 2,071,000                    
        total current liabilities
      		36,843,000 19,666,000 17,894,000 46,500,000 15,441,000 12,711,000 12,560,000 14,039,000 18,366,000 11,741 8,959,000 7,909,000 9,857 10,462,000 9,478,000 11,922,000 17,636 17,358,000 15,422,000 14,473,000 14,415,000 13,640,000 16,916,000 17,918,000 16,310,000 14,028,000 11,988,000 10,780,000 9,311,000 7,751,000 7,542,000 6,747,000 6,146,000 6,153,000 8,545,000 13,664,000 20,459,000 15,032,000 13,757,000 15,521,000 9,488,000 2,243,000 
        development financing liability - non-current portion
      		99,172,000                                          
        deferred collaboration revenue - non-current portion
      		1,100,000                                          
        lease liabilities - non-current portion
      		5,315,000                                          
        total liabilities
      		142,430,000 124,857,000 118,242,000 141,130,000 105,698,000 99,069,000 95,267,000 93,261,000 69,381,000 35,844 9,947,000 9,036,000 11,119 11,851,000 10,989,000 13,552,000 19,379 19,209,000 17,376,000 16,526,000 16,329,000 15,577,000 18,955,000 20,060,000 19,300,000 17,840,000 16,593,000 16,152,000 15,422,000 14,574,000 15,054,000 14,924,000 14,964,000 15,369,000 10,990,000 16,462,000 23,624,000 18,518,000 17,556,000 19,820,000 13,904,000 12,058,000 
        commitments and contingencies
      		                                          
        stockholders’ equity:
      		                                          
        preferred stock, 0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
      		                                          
        common stock
      		11,000 18,000 17,000 17,000 8,000 8,000 8,000 8,000 8,000 7 7,000 7,000 7 7,000 7,000 7,000 7 7,000 7,000 7,000 6,000 6,000 6,000 6,000 4,000 4,000 3,000 3,000 2,000 2,000 2,000 2,000 2,000 2,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 
        additional paid-in capital
      		1,270,328,000 1,262,560,000 1,010,958,000 1,005,877,000 909,329,000 906,968,000 904,609,000 902,217,000 899,798,000 827,365 824,717,000 822,054,000 819,549 817,653,000 815,101,000 814,131,000 812,133 808,866,000 806,001,000 803,718,000 693,534,000 691,771,000 684,326,000 679,846,000 535,503,000 531,986,000 439,376,000 437,536,000 426,895,000 426,219,000 425,552,000 424,981,000 424,422,000 423,809,000 402,136,000 401,361,000 394,622,000 394,182,000 370,552,000 370,276,000 367,435,000 365,033,000 
        accumulated other comprehensive income
      		144,000        -13,000 -1 1,000 -6,000 8 82,000 186,000 -130,000 80 177,000 228,000 45,000                 -14,000 -15,000  3,000 2,000  
        accumulated deficit
      		-978,227,000 -936,325,000 -902,443,000 -901,635,000 -872,857,000 -846,224,000 -821,719,000 -794,625,000 -766,856,000 -740,313 -717,631,000 -694,409,000 -676,858 -661,107,000 -649,686,000 -638,960,000 -625,872 -596,459,000 -570,177,000 -546,139,000 -523,064,000 -503,615,000 -485,052,000 -467,521,000 -450,516,000 -445,473,000 -437,239,000 -428,310,000 -422,959,000 -416,007,000 -410,128,000 -403,136,000 -396,288,000 -390,309,000 -384,444,000 -383,087,000 -380,759,000 -368,037,000 -362,076,000 -358,904,000 -348,842,000 -344,928,000 
        total stockholders’ equity
      		292,256,000 326,191,000 108,408,000 104,189,000 36,154,000 60,178,000 82,457,000 107,381,000 132,937,000 87,058 107,094,000 127,646,000 142,706 156,635,000 165,608,000 175,048,000 186,348 212,591,000 236,059,000 257,631,000 170,418,000 188,131,000 199,213,000 212,199,000 84,947,000 86,504,000 2,139,000 9,227,000 3,937,000 10,212,000 15,421,000 21,846,000 28,115,000 33,494,000 17,680,000 18,268,000 13,850,000 26,131,000 8,477,000 11,376,000 18,596,000 20,106,000 
        total liabilities and stockholders’ equity
      		434,686,000 451,048,000 226,650,000 245,319,000 141,852,000 159,247,000 177,724,000 200,642,000 202,318,000 122,902 117,041,000 136,682,000 153,825 168,486,000 176,597,000 188,600,000 205,727 231,800,000 253,435,000 274,157,000 186,747,000 203,708,000 218,168,000 232,259,000 104,247,000 104,344,000 18,732,000 25,379,000 19,359,000 24,786,000 30,475,000 36,770,000 43,079,000 48,863,000 28,670,000 34,730,000 37,474,000 44,649,000 26,033,000 31,196,000   
        operating lease right-of-use asset
      		 57,000 99,000 137,000 169,000 197,000 220,000 239,000 254,000 264 270,000 273,000 272 268,000 260,000 249,000  219,000 199,000 177,000                       
        deferred collaboration revenue—current portion
      		 1,632,000 1,632,000                                        
        development financing liability
      		 104,091,000 99,248,000 94,630,000 90,227,000 86,152,000 82,333,000 78,685,000 50,320,000 23,259                                 
        deferred collaboration revenue—non-current portion
      		 1,100,000 1,100,000                                        
        long-term portion of operating lease liability
      		    30,000 206,000 374,000 537,000 695,000 844 988,000 1,127,000 1,262 1,389,000 1,511,000 1,630,000 1,743 1,851,000 1,954,000 2,053,000                       
        accumulated other comprehensive loss
      		 -62,000 -124,000 -70,000 -326,000 -574,000 -441,000 -219,000             -58,000 -31,000 -67,000 -132,000 -44,000 -13,000 -1,000 -2,000 -1,000 -2,000 -5,000 -1,000 -21,000 -8,000 -13,000 -7,000       
        deferred collaboration revenue
      		   33,733,000                                       
        prepaid research and development expenses
      		     668,000 1,103,000 1,384,000 2,371,000 5,071 6,060,000 5,631,000 2,221 3,761,000 4,012,000 7,922,000 9,910 7,900,000                         
        other prepaid expenses and current assets
      		     1,041,000 1,625,000 2,103,000 2,193,000 648 1,392,000 1,919,000 2,764 820,000 974,000                            
        accrued interest receivable
      		         69 227,000 265,000 277 284,000 209,000 377,000 687 509,000 725,000 481,000  217,000 405,000       22,000 19,000 96,000 186,000 209,000 83,000 199,000 136,000 223,000 134,000 90,000 68,000  
        accrued restructuring
      		            18 93,000 879,000 1,717,000 3,193                          
        other prepaid expenses
      		               1,418,000 1,381 768,000                         
        operating lease right-of-use assets
      		                235                          
        other liabilities
      		                            13,000 14,000    18,000 16,000      9,000  
        prepaid expenses
      		                  7,881,000 4,827,000 2,594,000 1,793,000 2,131,000 1,367,000 1,208,000 1,368,000 1,126,000 1,128,000 1,369,000 1,324,000 1,029,000 1,140,000 1,128,000 1,491,000 996,000 1,363,000 1,991,000 1,402,000 1,475,000 1,876,000 364,000 33,000 
        accrued clinical trial expenses
      		                  9,274,000 9,281,000  9,574,000 7,877,000                    
        receivable from collaboration
      		                        5,000,000                  
        other current assets
      		                    304,000 2,100,000 2,100,000 273,000 126,000 122,000 17,000 33,000 165,000     20,000 176,000 139,000 96,000 134,000 187,000 266,000 453,000  
        accrued clinical expenses
      		                    8,588,000                      
        warrant liability
      		                      5,632,000 7,648,000 6,091,000 5,862,000 4,343,000 3,279,000 1,145,000 1,177,000 1,259,000 900,000 1,220,000 1,356,000 2,181,000 7,704,000 13,596,000 8,766,000 8,888,000 11,638,000 6,466,000  
        facility loan
      		                       3,219,000 3,108,000 3,001,000 2,897,000 2,797,000 2,700,000 2,607,000 2,041,000 1,262,000 509,000  1,450,000 1,403,000 1,355,000 1,193,000 795,000 410,000 38,000  
        accrued interest payable
      		                       37,000 43,000 49,000 55,000 60,000 66,000 72,000 73,000 73,000 73,000 73,000 29,000 32,000 35,000 36,000 36,000 36,000 36,000  
        deferred rent, less current portion
      		                    1,914,000                      
        facility loan, less current portion
      		                       2,142,000 2,990,000 3,809,000 4,599,000 5,362,000 6,098,000 6,809,000 7,496,000 8,159,000 8,799,000 9,198,000 2,429,000 2,784,000 3,152,000 3,476,000 3,793,000 4,099,000 4,407,000  
        deferred rent, net of current portion
      		                     1,937,000 2,039,000                    
        accrued liabilities
      		                       4,976,000 5,757,000 3,881,000 3,592,000 3,548,000 4,501,000 2,960,000 2,897,000 2,735,000 3,336,000 4,017,000 3,164,000 2,998,000 3,388,000 3,990,000 2,776,000 2,368,000 2,251,000 1,204,000 
        other liabilites
      		                         3,000 6,000 10,000   16,000 18,000 19,000   14,000 13,000 10,000 6,000 200,000   
        contract receivables
      		                                  17,000  211,000 14,000 10,000 168,000 110,000  
        liabilities and redeemable convertible preferred stock and stockholders’ equity
      		                                          
        convertible notes
      		                                          
        redeemable convertible preferred stock
      		                                          
        stockholders’ equity
      		                                          
        preferred stock, 0.0001 par value: 10,000,000 shares authorized at december 31, 2013; no shares authorized at december 31, 2012; no shares issued and outstanding
      		                                          
        total liabilities and redeemable convertible preferred stock and stockholders’ equity
      		                                        32,500,000 32,164,000 
        long term warrant liability
      		                                         5,310,000 
        deferred rent
      		                                         131,000 
        stockholders’ deficit:
      		                                          
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 
                                                 
          operating activities
        		                                         
          net income
        		-41,902,000 -33,882,000 -808,000 -28,778,000 -26,633,000 -24,505,000 -27,094,000 -27,769,000 -26,543,000 -22,682,000 -23,222,000 -17,551,000 35,184,014 -11,421,000 -10,726,000 -13,088,000 73,292,192 -26,282,000 -24,038,000 -23,075,000 -19,449,000 -18,563,000 -17,531,000 -17,005,000 -5,043,000 -8,234,000 -8,929,000 -5,351,000 -6,952,000 -5,879,000 -6,992,000 -6,848,000 -5,979,000 -5,865,000 -1,357,000 -2,328,000 -12,722,000 -5,961,000 -3,172,000 -10,062,000 -3,914,000 
          adjustments to reconcile net income to net cash from operating activities:
        		                                         
          depreciation and amortization
        		56,000 215,000 211,000 199,000 185,000 182,000 174,000 169,000 173,000 176,000 175,000 164,000 -467,368 159,000 156,000 153,000 -421,428 144,000 140,000 138,000 66,000 14,000 13,000 12,000 9,000 8,000 9,000 9,000 8,000 10,000 6,000 5,000 5,000 6,000 5,000 6,000 5,000 5,000 5,000 3,000 5,000 
          non-cash lease expense
        		                                         
          stock-based compensation expense
        		4,669,000 3,724,000 3,350,000 3,487,000 2,361,000 2,350,000 2,392,000 2,414,000 2,385,000 2,549,000 2,557,000 2,505,000 -5,505,865 2,552,000 963,000 1,998,000 -7,473,442 2,865,000 2,276,000 2,342,000 1,738,000 1,728,000 1,751,000 1,796,000 982,000 820,000 1,840,000 1,278,000              
          accretion of development financing liability
        		5,081,000 4,843,000 4,618,000 4,403,000 4,075,000 3,819,000 3,648,000 3,365,000 2,061,000                                 
          write-off of deferred financing costs
        		        0 0                                
          net amortization of investments in marketable securities
        		-2,462,000 -2,094,000                                        
          changes in assets and liabilities:
        		                                         
          prepaid expenses and other current assets
        		-746,000 745,000 -3,191,000 -3,767,000                                      
          other assets
        		80,000 -1,025,000 -121,000 1,176,000 224,000 -107,000 -578,000 -728,000 1,000 -274,000 -1,000 -1,239,000     -1,016,880 -531,000 392,000 1,158,000 -917,000 0 -383,000 -346,000 0 170,000      -53,000 20,000 227,000 -171,000 -42,000 38,000 408,000 -232,000 -211,000  
          accounts payable
        		1,097,000 -1,858,000 2,956,000 537,000 617,000 -387,000 667,000 -2,341,000 1,797,000 -286,000 -577,000 1,375,000 1,553,728 471,000 -737,000 -1,290,000 479,530 -1,388,000 472,000 437,000 344,000 293,000 -702,000 727,000 227,000 -17,000 5,000 197,000 -36,000 -337,000 -505,000 769,000 301,000 -1,014,000 194,000 -558,000 1,038,000 -215,000 193,000 372,000 -342,000 
          deferred collaboration revenue
        		57,000 0 -31,001,000 33,733,000                                      
          accrued research and development expenses
        		-202,000 997,000 -727,000 -965,000 -92,000 -406,000 -2,631,000 -93,000                                  
          other accrued liabilities
        		6,677,000 2,190,000 1,266,000 -2,276,000 1,977,000 828,000 322,000 -1,587,000                                  
          net cash from operating activities
        		-27,380,000 -26,145,000 -25,437,000 6,431,000  -17,522,000 -22,440,000 -25,362,000 -14,243,000 -15,413,000 -19,214,000 -20,561,000 29,864,275 -7,452,000 -7,749,000 -14,708,000 69,677,089 -23,127,000 -24,254,000 -22,394,000 -19,595,000 -16,077,000 -12,823,000 -6,441,000 -6,072,000 -5,466,000 -5,891,000 -2,203,000 -5,402,000 -5,741,000 -6,070,000 -6,140,000 -5,196,000 -6,660,000 -5,309,000 -6,159,000 -7,472,000 -3,892,000 -4,739,000 -5,011,000 -3,537,000 
          capital expenditures
        		-180,000 0 -70,000 -195,000  -11,000 0  0 0 7,000 -94,000 20,979 0 0  288,685 -20,000 -91,000 -178,000 -469,000 -14,000 0 -46,000 0 0 0 0 0 -5,000 0  0 0 0  0 -10,000 -61,000 -32,000 0 
          free cash flows
        		-27,560,000 -26,145,000 -25,507,000 6,236,000  -17,533,000 -22,440,000  -14,243,000 -15,413,000 -19,207,000 -20,655,000 29,885,254 -7,452,000 -7,749,000  69,965,774 -23,147,000 -24,345,000 -22,572,000 -20,064,000 -16,091,000 -12,823,000 -6,487,000 -6,072,000 -5,466,000 -5,891,000 -2,203,000 -5,402,000 -5,746,000 -6,070,000  -5,196,000 -6,660,000 -5,309,000  -7,472,000 -3,902,000 -4,800,000 -5,043,000 -3,537,000 
          investing activities
        		                                         
          purchases of property and equipment
        		-180,000 0 -70,000 -195,000 -13,000 -11,000   0 0 7,000 -94,000 20,979    288,685 -20,000 -91,000 -178,000 -469,000 -14,000 0 -46,000     0 -5,000       0 -10,000 -61,000 -32,000  
          purchases of marketable securities
        		-115,928,000 -29,538,000 -39,111,000 -121,097,000 -12,631,000 -46,883,000 -52,978,000 -62,485,000 -33,477,000 -10,787,000 -15,608,000 -18,212,000 153,774,700 -88,447,000 -1,000 -65,503,000 245,889,107 -24,902,000 -130,381,000 -90,897,000 -26,960,000 -63,497,000 -60,982,000 -124,943,000 -9,444,000 -79,119,000 -698,000 -9,124,000 -3,602,000 -1,600,000 -16,704,000 -1,000,000 -1,016,000 -28,397,000 -6,758,000 -6,617,000 -2,552,000 -13,590,000    
          proceeds from maturities of marketable securities
        		74,001,000 44,999,000 39,900,000 60,650,000 21,000,000 42,345,000 54,300,000 11,495,000 9,400,000 39,080,000 24,280,000 54,000,000 -206,053,722 47,142,000 47,000,000 112,136,000 -198,628,119 63,430,000 57,400,000 78,051,000 54,200,000 75,118,000 58,148,000 35,334,000 14,569,000 7,215,000 3,200,000 5,900,000 13,420,000 2,000,000            
          net cash from investing activities
        		-42,107,000 15,461,000   8,356,000 -4,549,000 1,198,000 -50,990,000 -24,077,000 28,293,000 8,679,000 35,694,000 -52,258,043 -41,326,000 46,999,000 46,633,000 43,573,653 38,508,000 -73,072,000 -9,044,000 26,771,000 11,607,000 -2,834,000 -89,655,000 5,098,000 -71,904,000 2,502,000 -3,224,000 9,818,000 395,000 -2,716,000 19,631,000 6,211,000 -24,947,000 6,554,000 1,099,000 2,898,000 -10,782,000 -9,604,000 550,000 -6,681,000 
          financing activities
        		                                         
          proceeds from issuance of common stock pursuant to equity award plans
        		3,173,000 5,699,000 1,050,000 710,000 0    14,000 99,000   -6,908 0   -103,614 0 7,000 97,000 24,000 26,000 245,000 3,276,000 1,749,000                 
          proceeds from issuance of common stock and pre-funded warrants, net of issuance costs
        		-444,000 243,224,000 0 92,360,000                                      
          proceeds from development financing, net of transaction costs
        		    0    24,650,000                                 
          net cash from financing activities
        		2,729,000 248,923,000 1,050,000 93,070,000 0 9,000 0 24,541,000 95,163,000        -107,741,868 0 -167,000 108,017,000 24,000 1,539,000 -5,198,000 138,623,000 1,019,000 90,870,000 -775,000 8,605,000 -742,000    0 26,596,000 -384,000 4,315,000 -196,000 23,028,000 3,000 2,402,000 2,539,000 
          net increase in cash, cash equivalents and restricted cash
        		                                         
          cash, cash equivalents, and restricted cash at beginning of period
        		                                         
          cash, cash equivalents, and restricted cash at end of period
        		                                         
          supplemental disclosures:
        		                                         
          supplemental operating activities
        		                                         
          cash paid for amounts included in the measurement of lease liabilities
        		233,000 176,000 177,000 176,000 173,000 171,000 171,000 171,000 168,000 166,000 166,000 166,000 -483,353 161,000 162,000 161,000 -469,372 157,000                        
          supplemental non-cash investing and financing activities
        		                                         
          right-of-use assets acquired in exchange for operating lease liabilities
        		                                         
          right-of-use assets acquired in exchange for finance lease liabilities
        		                                         
          accrued financing costs
        		         257,000          174,000                      
          proceeds from development financing
        		      0 25,000,000                                  
          net increase in cash and cash equivalents
        		 238,239,000 -23,668,000 38,859,000 -10,400,000 -22,062,000 -21,242,000 -51,811,000 56,843,000 36,066,000 -10,429,000 15,133,000 -22,400,676 -48,778,000 39,257,000 31,925,000 5,508,874 15,381,000 -97,493,000 76,579,000 7,200,000 -2,931,000 -20,855,000 42,527,000 45,000 13,500,000 -4,164,000 3,178,000   -8,786,000 13,491,000     -4,770,000     
          cash and cash equivalents at beginning of period
        		 0 0 20,291,000 0 0 0 125,806,000 0 0 0 28,193,000 -24,844,131 0 0 24,869,000 -48,946,005 0 0 48,995,000 0 0 0 23,054,000 0 0 0 10,495,000 0 0 0 7,706,000 0 0 0 11,586,000 0 0 0 24,401,000  
          cash and cash equivalents at end of period
        		 238,239,000 -23,668,000 59,150,000 -10,400,000 -22,062,000 -21,242,000 73,995,000 56,843,000 36,066,000 -10,429,000 43,326,000 -47,244,807 -48,778,000 39,257,000 56,794,000 -43,437,131 15,381,000 -97,493,000 125,574,000 7,200,000 -2,931,000 -20,855,000 65,581,000 45,000 13,500,000 -4,164,000 13,673,000 3,674,000 -5,590,000 -8,786,000 21,197,000 1,015,000 -5,011,000 861,000 10,841,000 -4,770,000 8,354,000 -14,340,000 22,342,000  
          unsettled stock option exercise
        		                                         
          accrued costs for other assets
        		                                         
          supplemental non-cash financing activities
        		                                         
          unsettled stock option exercise proceeds
        		                                         
          net accretion and amortization of investments in marketable securities
        		   -1,318,000 -591,000 -315,000 -99,000 131,000 94,000 117,000 230,000 196,000 239,896 66,000 -101,000 -205,000 1,906,763 -585,000 -780,000 -544,000 -587,000 -581,000 -499,000 -278,000                  
          net cash (used in) investing activities
        		   -60,642,000                                      
          supplemental disclosure
        		                                         
          net cash (used in) operating activities
        		                                         
          unpaid financing costs
        		                                         
          other prepaid expenses and current assets
        		     1,019,000 759,000 1,077,000                                  
          issuance costs paid for issuance of common stock
        		     0 0 -459,000                                  
          accrued financing costs in accounts payable
        		                                         
          interest receivable and other current assets
        		         587,000 -121,000 299,000 -42,361 -436,000 168,000 310,000 204,617 216,000 -244,000 -177,000  186,000                    
          prepaid expenses
        		            -7,063,923 561,000    -787,000 -3,054,000 -2,233,000 -801,000 338,000 -764,000 -159,000 160,000 -242,000 2,000 241,000 -565,000 -295,000 58,000 41,000 363,000 -495,000 367,000 628,000 -589,000 73,000 401,000 -1,512,000 -331,000 
          accrued liabilities
        		         2,575,000 1,374,000 -3,458,000 2,869,187 1,382,000 -1,193,000 -3,061,000 -3,363,669 3,221,000 582,000 -440,000 205,000 2,054,000 4,972,000 -781,000 1,873,000 286,000 40,000 -812,000 1,391,000 63,000 163,000 -602,000 -681,000 853,000 166,000 -390,000 -602,000 1,214,000 447,000 830,000 189,000 
          prepaid research and development expenses and other prepaid assets
        		          59,000 -2,852,000    1,951,000                          
          cash from financing activities
        		            -6,908                             
          accelerated vesting of stock-based compensation due to restructuring
        		                                         
          accrued restructuring charges
        		            3,096,825 -786,000 -838,000 -1,476,000                          
          proceeds from sale of marketable securities
        		                -3,976,020 0 0 3,980,000                      
          proceeds from issuance of common stock, net of issuance costs
        		                -107,638,254 0 -174,000 107,920,000 0 0 0 135,520,000 -151,000 91,223,000 0 9,364,000        4,263,000      
          supplemental disclosures
        		                                         
          operating lease right-of-use assets obtained in exchange for lease liabilities
        		                                         
          accelerated vesting of stock-based compensation expense due to restructuring
        		                                         
          non-cash interest associated with debt discount accretion
        		                    0 0 56,000 92,000 98,000 107,000 112,000 120,000 124,000 123,000   76,000 66,000 50,000 36,000 54,000 53,000 42,000 49,000  
          loss on extinguishment of debt
        		                    0 0                    
          change in fair value of warrant liability
        		                    0 -1,031,000 87,000 4,654,000 777,000 1,798,000 1,064,000 2,134,000 -32,000 -82,000 359,000 -320,000 -136,000 -1,083,000 -5,327,000 -4,575,000 4,947,000 255,000 -2,750,000 4,784,000  
          gain on extinguishment of warrant liability
        		                    0                     
          accretion of tenant improvement allowance
        		                    -109,000 -93,000                    
          receivable from collaboration
        		                    0 0                    
          prepaid research and development and other prepaid expenses
        		                                         
          accrued restructuring
        		                                         
          accrued interest payable
        		                    0 0 -37,000 -6,000 -6,000 -6,000 -5,000 -6,000 -6,000    34,000 71,000 23,000 15,000 27,000 28,000 26,000 26,000 60,000 
          proceeds from issuance of common stock upon exercise of warrants
        		                    0 1,513,000 381,000 656,000                  
          repayment of facility loan principal
        		                    0 0 -5,698,000 -829,000 -810,000 -793,000 -775,000 -759,000              
          payment of fees to extinguish facility loan
        		                    0 0                    
          cash paid for interest
        		                    0 0 108,000 123,000         219,000 122,000 93,000 101,000 107,000 109,000 110,000 109,000  
          issuance of common stock upon warrant exercises
        		                    0 4,179,000 2,103,000 3,097,000         0 0 196,000 1,317,000      
          lessor funded lease incentives included in property and equipment
        		                                         
          accrued property and equipment
        		                                         
          lessor funded lease incentives included in other current assets
        		                     0                    
          other current assets
        		                       -147,000 3,000 -105,000 16,000 -12,000              
          net change in accrued financing costs
        		                                         
          accounts receivable
        		                       5,000,000                  
          accretion and amortization of marketable securities
        		                         -51,000 5,000 -1,000              
          amortization of premium on marketable securities
        		                            -3,000 -5,000 27,000 106,000 164,000 119,000 61,000 167,000 164,000 111,000 107,000 71,000  
          proceeds from facility loan
        		                                0        0 
          proceeds from issuance of common stock and warrants, net of issuance costs
        		                                    0 23,028,000 0 2,402,000  
          supplemental non-cash investing and financing activites
        		                                         
          issuance of common stock warrants to lenders
        		                                         
          stock based compensation expense
        		                             667,000            
          contract receivables
        		                                0 17,000 -17,000 211,000 -197,000 -4,000 158,000 -58,000 -110,000 
          accrued interest receivable
        		                             -3,000 77,000 90,000 23,000 -126,000 116,000 -63,000 87,000 -89,000 -44,000 -22,000 -68,000 
          other liabilities
        		                             -2,000   1,000 2,000 2,000 1,000 3,000 4,000 3,000 3,000  
          repayment of loan principal
        		                                  -384,000 -374,000      
          proceeds from issuance of common stock upon warrant exercises
        		                                 0 0 426,000      
          net decrease in cash and cash equivalents
        		                                1,015,000   -745,000   -14,340,000 -2,059,000  
          non-employee stock-based compensation expense
        		                               3,000 -1,000 0 -6,000 28,000 3,000 2,000 1,000 2,000  
          employee and director stock-based compensation expense
        		                               556,000 614,000 562,000 585,000 705,000 272,000 223,000 75,000 714,000 826,000 
          non-cash interest associated with debt discount and final payment accretion
        		                               113,000          
          proceeds from sales and maturities of marketable securities
        		                               20,631,000 7,227,000 3,450,000 13,312,000 7,716,000 5,450,000     
          loss on sale of property and equipment
        		                                         
          proceeds from issuance of common stock upon exercise of stock options
        		                                         
          supplemental disclosure of cash flow information
        		                                         
          noncash issuance costs incurred in common stock financing
        		                                    0 0 0 453,000  
          reclassification of incentive awards to equity
        		                                    0 1,000    
          proceeds from issuance of common stock and warrants, net of costs
        		                                         
          payment of loan principal
        		                                         
          proceeds from issuance of common stock upon exercise of employee stock options
        		                                    2,000 0    
          issuance of common stock warrants
        		                                      0 443,000  
          fixed assets in accrued expenses
        		                                       28,000  
          amortization of notes payable conversion option
        		                                        0 
          gain on sale of property and equipment
        		                                    0 1,000   -207,000 
          proceeds from sale of property and equipment
        		                                         
          repurchase of preferred stock
        		                                        0 
          financing costs in accrued expenses
        		                                         
          fair value of forward contract
        		                                         
          issuance of common stock warrants to common stockholders
        		                                         
          conversion of preferred shares into common stock
        		                                         
          issuance of common stock for debt extinguishment
        		                                        0 
          issuance of common stock warrants-lenders
        		                                         
          issuance of common stock warrants-common stock
        		                                         
          issuance of common stock upon cashless warrant exercise
        		                                     377,000 0 55,000  
          proceeds from sales of marketable securities
        		                                      1,649,000 582,000  
          proceeds from the sale of property and equipment
        		                                         
          principal payments on equipment loans
        		                                         
          net increase(decrease) in cash and cash equivalents
        		                                         
          cash and cash equivalents at beginning of year
        		                                        0 
          cash and cash equivalents at end of year
        		                                        -7,679,000 
          interest paid
        		                                         
          conversion of preferred stock into common stock
        		                                         
          non-cash interest associated with discount accretion
        		                                         
          deferred rent
        		                                         
          deferred revenue
        		                                         
          proceeds from issuance of commons stock and warrants, net of issuance costs